01540nas a2200265   4500000000100000008004100001653002800042653002400070653000900094653002500103653001100128653001600139653001000155100001400165700001300179700001300192700001400205700001200219245010700231856005100338300001000389490000700399520085400406022001401260       2015                            d10aTuberculosis, Cutaneous10aMycobacterium bovis10aMale10aLeprosy, lepromatous10aHumans10aBCG Vaccine10aAdult1 aKhullar G1 aNarang T1 aSharma K1 aSaikia UN1 aDogra S00aDisseminated cutaneous BCG infection following BCG immunotherapy in patients with lepromatous leprosy.  uhttps://leprosyreview.org/article/86/2/19-1907  a180-50 v863 a<p>Cutaneous complications of Bacillus Calmette-Guerin (BCG) vaccine, especially in the form of generalised disease, are uncommon and mostly occur in immunocompromised individuals. There is a paucity of data on the cutaneous adverse reactions secondary to BCG immunotherapy in leprosy. We report two unique cases of disseminated cutaneous BCG infection following immunotherapy in patients with lepromatous leprosy. To our knowledge, cutaneous BCG infection presenting as widespread lesions after immunotherapy and confirmed by isolation of Mycobacterium bovis by polymerase chain reaction (PCR) has not been described. A high index of suspicion is required when leprosy patients who receive BCG immunotherapy develop new lesions that cannot be classified as either reaction or relapse, and diagnosis may be confirmed on histopathology and PCR.</p>
  a0305-7518